Compare TCI & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCI | TLSI |
|---|---|---|
| Founded | 1983 | 2010 |
| Country | United States | United States |
| Employees | N/A | 102 |
| Industry | Real Estate | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.7M | 270.2M |
| IPO Year | 1994 | N/A |
| Metric | TCI | TLSI |
|---|---|---|
| Price | $38.17 | $4.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 3.3K | ★ 137.9K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 135.29 | N/A |
| EPS | ★ 1.60 | N/A |
| Revenue | ★ $49,060,000.00 | N/A |
| Revenue This Year | N/A | $35.45 |
| Revenue Next Year | N/A | $37.58 |
| P/E Ratio | $22.99 | ★ N/A |
| Revenue Growth | ★ 4.23 | N/A |
| 52 Week Low | $27.06 | $3.42 |
| 52 Week High | $59.65 | $7.95 |
| Indicator | TCI | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 50.07 | 54.33 |
| Support Level | $33.50 | $4.28 |
| Resistance Level | $42.76 | $4.83 |
| Average True Range (ATR) | 1.22 | 0.23 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 33.38 | 58.14 |
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates in two business segments: the acquisition, development, ownership and management of multifamily properties; and the acquisition, development, ownership and management of commercial properties; which are office properties. The services for its commercial segment include rental of office space and other tenant services, including parking and storage space rental. The services for its multifamily segment include rental of apartments and other tenant services, including parking and storage space rental. the company derives maximum revenue from Multifamily Segment.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.